vs
Orthofix Medical Inc.（OFIX）与Zeta Global Holdings Corp.（ZETA）财务数据对比。点击上方公司名可切换其他公司
Zeta Global Holdings Corp.的季度营收约是Orthofix Medical Inc.的1.8倍（$394.6M vs $219.9M），Zeta Global Holdings Corp.净利率更高（1.7% vs -1.0%，领先2.7%），Zeta Global Holdings Corp.同比增速更快（25.4% vs 2.0%），Zeta Global Holdings Corp.自由现金流更多（$60.9M vs $16.8M），过去两年Zeta Global Holdings Corp.的营收复合增速更高（42.3% vs 8.0%）
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
Zeta Global Holdings Corp是一家2007年成立的美国营销科技企业，为各公司提供多渠道营销工具矩阵，核心业务围绕客户关系的构建、维护与价值变现展开。该公司于2021年6月10日在纽约证券交易所上市，上市时估值达17亿美元。
OFIX vs ZETA — 直观对比
营收规模更大
ZETA
是对方的1.8倍
$219.9M
营收增速更快
ZETA
高出23.4%
2.0%
净利率更高
ZETA
高出2.7%
-1.0%
自由现金流更多
ZETA
多$44.1M
$16.8M
两年增速更快
ZETA
近两年复合增速
8.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $219.9M | $394.6M |
| 净利润 | $-2.2M | $6.5M |
| 毛利率 | 71.1% | 59.5% |
| 营业利润率 | 0.2% | 4.5% |
| 净利率 | -1.0% | 1.7% |
| 营收同比 | 2.0% | 25.4% |
| 净利润同比 | 92.4% | -57.1% |
| 每股收益（稀释后） | $-0.05 | $0.04 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OFIXZETA
| Q4 25 | $219.9M | $394.6M | ||
| Q3 25 | $205.6M | $337.2M | ||
| Q2 25 | $203.1M | $308.4M | ||
| Q1 25 | $193.6M | $264.4M | ||
| Q4 24 | $215.7M | $314.7M | ||
| Q3 24 | $196.6M | $268.3M | ||
| Q2 24 | $198.6M | $227.8M | ||
| Q1 24 | $188.6M | $194.9M |
净利润OFIXZETA
| Q4 25 | $-2.2M | $6.5M | ||
| Q3 25 | $-22.8M | $-3.6M | ||
| Q2 25 | $-14.1M | $-12.8M | ||
| Q1 25 | $-53.1M | $-21.6M | ||
| Q4 24 | $-29.1M | $15.2M | ||
| Q3 24 | $-27.4M | $-17.4M | ||
| Q2 24 | $-33.4M | $-28.1M | ||
| Q1 24 | $-36.0M | $-39.6M |
毛利率OFIXZETA
| Q4 25 | 71.1% | 59.5% | ||
| Q3 25 | 72.2% | 60.5% | ||
| Q2 25 | 68.7% | 62.1% | ||
| Q1 25 | 62.8% | 60.9% | ||
| Q4 24 | 69.0% | 60.0% | ||
| Q3 24 | 68.7% | 60.6% | ||
| Q2 24 | 67.8% | 60.0% | ||
| Q1 24 | 67.5% | 60.6% |
营业利润率OFIXZETA
| Q4 25 | 0.2% | 4.5% | ||
| Q3 25 | -8.3% | 2.6% | ||
| Q2 25 | -7.9% | -1.7% | ||
| Q1 25 | -25.2% | -6.1% | ||
| Q4 24 | -5.3% | 2.2% | ||
| Q3 24 | -9.6% | -4.6% | ||
| Q2 24 | -12.5% | -11.7% | ||
| Q1 24 | -15.6% | -18.4% |
净利率OFIXZETA
| Q4 25 | -1.0% | 1.7% | ||
| Q3 25 | -11.1% | -1.1% | ||
| Q2 25 | -6.9% | -4.2% | ||
| Q1 25 | -27.4% | -8.2% | ||
| Q4 24 | -13.5% | 4.8% | ||
| Q3 24 | -13.9% | -6.5% | ||
| Q2 24 | -16.8% | -12.3% | ||
| Q1 24 | -19.1% | -20.3% |
每股收益（稀释后）OFIXZETA
| Q4 25 | $-0.05 | $0.04 | ||
| Q3 25 | $-0.57 | $-0.02 | ||
| Q2 25 | $-0.36 | $-0.06 | ||
| Q1 25 | $-1.35 | $-0.10 | ||
| Q4 24 | $-0.76 | $0.10 | ||
| Q3 24 | $-0.71 | $-0.09 | ||
| Q2 24 | $-0.88 | $-0.16 | ||
| Q1 24 | $-0.95 | $-0.23 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $82.0M | $319.8M |
| 总债务越低越好 | — | $197.1M |
| 股东权益账面价值 | $450.0M | $804.6M |
| 总资产 | $850.6M | $1.5B |
| 负债/权益比越低杠杆越低 | — | 0.24× |
8季度趋势，按日历期对齐
现金及短期投资OFIXZETA
| Q4 25 | $82.0M | $319.8M | ||
| Q3 25 | $62.9M | $385.2M | ||
| Q2 25 | $65.6M | $365.3M | ||
| Q1 25 | $58.0M | $364.4M | ||
| Q4 24 | $83.2M | $366.2M | ||
| Q3 24 | $30.1M | $418.5M | ||
| Q2 24 | $26.4M | $154.7M | ||
| Q1 24 | $27.0M | $141.6M |
总债务OFIXZETA
| Q4 25 | — | $197.1M | ||
| Q3 25 | $157.2M | $196.9M | ||
| Q2 25 | $157.0M | $196.7M | ||
| Q1 25 | $156.9M | $196.5M | ||
| Q4 24 | $157.0M | $196.3M | ||
| Q3 24 | $118.5M | $196.1M | ||
| Q2 24 | $118.0M | $184.4M | ||
| Q1 24 | $118.2M | $184.2M |
股东权益OFIXZETA
| Q4 25 | $450.0M | $804.6M | ||
| Q3 25 | $442.5M | $689.2M | ||
| Q2 25 | $458.3M | $673.3M | ||
| Q1 25 | $458.3M | $676.6M | ||
| Q4 24 | $503.1M | $676.8M | ||
| Q3 24 | $525.9M | $474.9M | ||
| Q2 24 | $546.0M | $217.0M | ||
| Q1 24 | $570.3M | $191.6M |
总资产OFIXZETA
| Q4 25 | $850.6M | $1.5B | ||
| Q3 25 | $832.6M | $1.2B | ||
| Q2 25 | $837.2M | $1.1B | ||
| Q1 25 | $823.1M | $1.1B | ||
| Q4 24 | $893.3M | $1.1B | ||
| Q3 24 | $867.9M | $869.1M | ||
| Q2 24 | $882.0M | $583.9M | ||
| Q1 24 | $906.0M | $550.3M |
负债/权益比OFIXZETA
| Q4 25 | — | 0.24× | ||
| Q3 25 | 0.36× | 0.29× | ||
| Q2 25 | 0.34× | 0.29× | ||
| Q1 25 | 0.34× | 0.29× | ||
| Q4 24 | 0.31× | 0.29× | ||
| Q3 24 | 0.23× | 0.41× | ||
| Q2 24 | 0.22× | 0.85× | ||
| Q1 24 | 0.21× | 0.96× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $27.7M | $64.1M |
| 自由现金流经营现金流 - 资本支出 | $16.8M | $60.9M |
| 自由现金流率自由现金流/营收 | 7.6% | 15.4% |
| 资本支出强度资本支出/营收 | 4.9% | 0.8% |
| 现金转化率经营现金流/净利润 | — | 9.81× |
| 过去12个月自由现金流最近4个季度 | $-1.3M | $185.1M |
8季度趋势，按日历期对齐
经营现金流OFIXZETA
| Q4 25 | $27.7M | $64.1M | ||
| Q3 25 | $12.4M | $57.9M | ||
| Q2 25 | $11.6M | $42.0M | ||
| Q1 25 | $-18.4M | $34.8M | ||
| Q4 24 | $23.7M | $43.7M | ||
| Q3 24 | $11.7M | $34.4M | ||
| Q2 24 | $9.0M | $31.1M | ||
| Q1 24 | $-18.6M | $24.7M |
自由现金流OFIXZETA
| Q4 25 | $16.8M | $60.9M | ||
| Q3 25 | $2.5M | $52.4M | ||
| Q2 25 | $4.5M | $39.7M | ||
| Q1 25 | $-25.1M | $32.1M | ||
| Q4 24 | $15.2M | $35.4M | ||
| Q3 24 | $6.3M | $29.5M | ||
| Q2 24 | $-360.0K | $24.4M | ||
| Q1 24 | $-29.1M | $18.9M |
自由现金流率OFIXZETA
| Q4 25 | 7.6% | 15.4% | ||
| Q3 25 | 1.2% | 15.6% | ||
| Q2 25 | 2.2% | 12.9% | ||
| Q1 25 | -13.0% | 12.1% | ||
| Q4 24 | 7.0% | 11.3% | ||
| Q3 24 | 3.2% | 11.0% | ||
| Q2 24 | -0.2% | 10.7% | ||
| Q1 24 | -15.4% | 9.7% |
资本支出强度OFIXZETA
| Q4 25 | 4.9% | 0.8% | ||
| Q3 25 | 4.8% | 1.6% | ||
| Q2 25 | 3.5% | 0.8% | ||
| Q1 25 | 3.5% | 1.0% | ||
| Q4 24 | 4.0% | 2.6% | ||
| Q3 24 | 2.7% | 1.8% | ||
| Q2 24 | 4.7% | 3.0% | ||
| Q1 24 | 5.6% | 3.0% |
现金转化率OFIXZETA
| Q4 25 | — | 9.81× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 2.87× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
ZETA
暂无分部数据
